Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →A grade PMID 42248607
View analysis →A grade PMID 41667193
View analysis →This single-center phase 1 study treated three pediatric patients with relapsed/refractory AML, plus one adult through compassionate access, with donor-derived multiplex base-edited anti-CD33 CAR T cells, demonstrating manufacturing and delivery feasibility, manageable but substantial toxicities, and minimal residual disease reductions in two patients who proceeded to allogeneic transplantation, although the primary endpoints were not met.
The reported evidence shows that BE-CAR33 cells can be administered as an off-the-shelf bridge to allogeneic transplantation and can produce measurable disease reduction in some patients; it remains an inference requiring larger controlled studies that multiplex editing, donor sourcing, and potentially multiantigen targeting will provide a safe, durable, and broadly effective AML therapy.
This narrative review synthesizes 18 preclinical, translational, and early-phase studies and compares eligibility criteria across 12 registered CNS CAR T-cell trials, highlighting preliminary activity, target-specific opportunities, toxicities, and barriers in pediatric brain tumors.
The supplied evidence suggests that locoregional or otherwise CNS-accessible CAR T cells directed against targets such as B7-H3 or GD2 may benefit selected pediatric brain tumors; multi-antigen targeting and modified CAR designs could theoretically limit antigen escape or improve activity, but these strategies remain investigational and are not established as safe or effective therapies.
In a multicenter, nonrandomized phase 1/2 trial, first-line avelumab plus methotrexate produced serum hCG normalization in 96.2% of 26 assessable patients with low-risk gestational trophoblastic tumors, with manageable reported toxicity, no relapses at a median 41-month follow-up, and pregnancies in 13 of 14 patients who intended pregnancy.
The trial provides preliminary human evidence that adding PD-L1 blockade to methotrexate can achieve durable hCG normalization while preserving fertility in low-risk GTT; it is an inference, not yet comparative evidence, that this combination improves cure rates or is especially beneficial for patients at higher risk of methotrexate resistance.
In a multicentre, single-arm phase 1/2 trial of 55 medically fit adults with relapsed or refractory acute myeloid leukaemia, venetoclax plus cytarabine and mitoxantrone produced a 75% composite complete remission rate, with febrile neutropenia and serious infections prominent and four potentially treatment-related deaths reported.
The trial provides clinical evidence that adding venetoclax to intensive cytarabine–mitoxantrone salvage therapy has activity in fit adults with relapsed or refractory AML; it is reasonable but still inferential to hypothesize that this regimen could improve remission induction and enable more patients to proceed to allogeneic HCT, because efficacy was not compared with a control group and pediatric applicability was not tested.
In a prospective phase II study of 68 patients with resectable head and neck squamous cell carcinoma receiving perioperative pembrolizumab, a genome-wide cfDNA end-motif entropy metric distinguished immunotherapy responders from nonresponders and was associated with disease-free survival.
The study provides evidence that longitudinal regional cfDNA motif diversity correlates with pembrolizumab response; it supports, but does not establish, the hypothesis that rMDS could enable minimally invasive response monitoring or risk stratification after prospective external validation.
In a 39-patient, open-label, single-arm phase 2 study of high-risk neuroblastoma, racotumomab induced anti-mouse and NeuGc-directed immune responses, including ADCC in a minority of patients, with no serious treatment-related adverse events and an exploratory association between IgM response and progression-free survival.
The study provides evidence that racotumomab can elicit NeuGc glycoconjugate-directed antibodies and occasional ADCC in children with high-risk neuroblastoma; it supports, but does not establish, the hypothesis that vaccine-induced immunity against tumor-associated NeuGcGM3 could help control residual disease, particularly in immunologic responders.
In a randomized 35-patient trial of children with newly diagnosed high-risk neuroblastoma and non-progressive disease after intensive initial therapy, dinutuximab alternating with G-CSF/teceleukin produced survival estimates interpreted as comparable to the ANBL0032-based GM-CSF/aldesleukin/isotretinoin regimen, without an obvious difference in frequently recorded grade 3/4 toxicities.
The trial provides preliminary clinical evidence that G-CSF/teceleukin may serve as an alternative cytokine regimen with dinutuximab where GM-CSF, aldesleukin, and isotretinoin are unavailable; equivalence or noninferiority remains an inference requiring confirmation in a larger phase III trial.
In a 650-patient randomized phase III trial of previously untreated, low-risk DLBCL in patients aged 18-80 years, PET-guided reduction to four R-CHOP cycles for early PET-negative patients was noninferior to six cycles and was associated with fewer grade ≥3 and serious adverse events.
The trial directly supports, in the studied adult and young-adult low-risk DLBCL population, the hypothesis that PET negativity after two R-CHOP cycles can identify patients who may receive four rather than six cycles without compromising 3-year progression-free survival while reducing toxicity; application to children or broader-risk DLBCL populations remains an inference not tested by this record.
This phase 1/2 TACL study of 24 pediatric patients with relapsed/refractory ALL found that ixazomib could be combined with relapse chemotherapy at an RP2D of 2 mg/m², with reported acceptable safety, a 67% complete response rate among evaluable patients, and flow MRD negativity in 9 of 14 responders.
The study provides early clinical evidence that adding the oral proteasome inhibitor ixazomib to established relapse chemotherapy is feasible and may have antileukemic activity in pediatric relapsed/refractory ALL; whether ixazomib improves response durability or survival beyond chemotherapy alone remains an untested inference requiring controlled trials.
In this global phase 3 trial of 899 randomized adults with previously untreated high-risk DLBCL or HGBL, adding tafasitamab and lenalidomide to R-CHOP improved progression-free survival but increased grade 3 or higher and fatal treatment-emergent adverse events, while overall-survival results remained immature.
The trial provides evidence that adding anti-CD19 tafasitamab and lenalidomide to first-line R-CHOP can reduce the risk of progression or death in high-risk adult DLBCL or HGBL; it remains an inference that this benefit will translate into longer overall survival or a favorable net clinical benefit, and the supplied record does not establish efficacy or safety in pediatric patients.
The study reports that linsitinib or selective FECH inhibition lowers heme and energy production in chronically antigen-activated GD2.CAR T cells, shifts them toward a less activated/exhausted central-memory phenotype, and that linsitinib enhances CAR T-cell activity against linsitinib-sensitive neuroblastoma cell lines.
Supported by the reported experiments, FECH inhibition alters heme-dependent CAR T-cell metabolism and phenotype; it is therefore hypothesized—but not clinically demonstrated here—that controlled FECH targeting or linsitinib treatment could improve GD2.CAR T-cell persistence and efficacy in neuroblastoma.
In a temozolomide-resistant Th-MYCN neuroblastoma mouse model and derived allografts, molecular profiling identified CDK2-pathway deregulation, and fadraciclib treatment produced significant tumor responses and an overall-survival benefit.
The supplied preclinical evidence supports activity of the CDK2/9 inhibitor fadraciclib in temozolomide-resistant neuroblastoma; it is reasonable, but not yet clinically demonstrated, to hypothesize that CDK2/9 inhibition could overcome or exploit resistance-associated dependencies in relapsed neuroblastoma and improve responses to temozolomide-based therapy.
